#Neurocrine #Neuroscience #R&D Day

Neurocrine Biosciences Announces 2025 R&D Day

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has confirmed that it will be hosting its 2025 R&D Day on December 16, 2025. The event is scheduled to begin at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) and will take place in San Diego, California. This event marks a significant opportunity for Neurocrine to showcase its ongoing transformation in research and development (R&D) and to provide an update on the various programs within its neuroscience pipeline.

During the R&D Day, key discussions will revolve around the company's advancements in understanding and treating neurological, neuroendocrine, and neuropsychiatric disorders. Attendees can expect insights into how Neurocrine’s innovative approaches are set to reshape the treatment landscape for patients with these conditions, which often go unaddressed.

One of the standout features of this year’s event will be a guest presentation from Dr. John Krystal, a Professor of Psychiatry, Neuroscience, and Psychology at Yale University. Dr. Krystal is a well-respected figure in the field and will provide key insights into the evolving science of neuroscience and its implications for treatment.

For those unable to attend in person, Neurocrine will offer a live webcast of the event. Interested individuals can access the webcast through the company's investor relations page at www.neurocrine.com. Approximately one hour after the event concludes, a recorded version of the webcast will be available, allowing both investors and the public to stay informed about Neurocrine's developments and plans for the future.

About Neurocrine Biosciences

Neurocrine Biosciences is dedicated to relieving the suffering of individuals affected by neurological disorders by delivering life-changing treatments. With over 30 years of experience in neuroscience, the company has built a portfolio that includes FDA-approved medications for various conditions, including tardive dyskinesia and certain types of hormone-related disorders. The company is committed to advancing research on complex diseases and enhancing patients' quality of life through groundbreaking science.

Neurocrine's robust pipeline features multiple candidates currently in mid- to late-phase clinical development, covering key therapeutic areas relevant to its mission. The company believes in the power of